Short answer · Medically reviewed summary · Last updated: 2026-05-08
Central Core Disease was first identified in 1956 by Shy and Magee, who described it as a non-progressive congenital myopathy characterized by muscle weakness and specific histological features. Since that initial discovery, our understanding of Central Core Disease has transitioned from a purely descriptive muscle pathology to a well-defined genetic condition linked primarily to mutations in the RYR1 gene. When and how was Central Core Disease first described? The medical history of Central Core Disease began in 1956 when physicians G.
What is the history of Central Core Disease?
History of Central Core Disease: when and how it was discovered, and the milestones in research since, medically reviewed.
Central Core Disease was first identified in 1956 by Shy and Magee, who described it as a non-progressive congenital myopathy characterized by muscle weakness and specific histological features. Since that initial discovery, our understanding of Central Core Disease has transitioned from a purely descriptive muscle pathology to a well-defined genetic condition linked primarily to mutations in the RYR1 gene.
When and how was Central Core Disease first described?
The medical history of Central Core Disease began in 1956 when physicians G. Milton Shy and Kenneth R. Magee published a landmark paper in the journal Brain. They identified five patients from a single family who exhibited congenital hypotonia and weakness. Using newly developed muscle biopsy techniques, they observed distinct "central cores" in the muscle fibers, which lacked oxidative enzyme activity, leading to the name Central Core Disease.
How has our understanding of the condition evolved?
For decades, clinicians viewed Central Core Disease as a static, non-progressive muscular disorder. However, the late 20th century brought a paradigm shift. In 1993, researchers linked the condition to the RYR1 gene, which encodes the ryanodine receptor—the calcium release channel in skeletal muscle. This breakthrough connected Central Core Disease to malignant hyperthermia, a life-threatening reaction to certain anesthetics, fundamentally changing how patients are managed before and during surgery.
What are the major milestones in the study of Central Core Disease?
- 1956: Initial clinical characterization by Shy and Magee.
- 1993: Mapping of the condition to the RYR1 gene on chromosome 19q13.
- 2000s: Recognition of the strong clinical overlap between Central Core Disease and susceptibility to malignant hyperthermia.
- Present: Growing community engagement through platforms like DiseaseMaps.org, where 89 members currently share their lived experiences to accelerate research.
Next steps
- Consult a neuromuscular specialist or geneticist for definitive molecular testing.
- Ensure all medical records clearly state a diagnosis of Central Core Disease to prevent the administration of triggering agents for malignant hyperthermia.
- Join the 89 members on DiseaseMaps.org to connect with others and stay updated on the latest research.
Medical disclaimer: This content is for informational purposes only and does not constitute professional medical advice, diagnosis, or treatment.
References
- NIH Genetic and Rare Diseases Information Center (GARD): Central Core Disease.
- OMIM (Online Mendelian Inheritance in Man): #117000 Central Core Disease of Muscle.
- Orphanet: Central Core Disease.
- Shy, G. M., & Magee, K. R. (1956). A new congenital non-progressive myopathy. Brain.
